Heska Corp (HSKA) was Initiated by Sidoti to “Buy”. Sidoti advised their investors in a research report released on Jul 1, 2016.
Heska Corp closed down -0.03 points or -0.08% at $35.69 with 65,093 shares getting traded on Wednesday. Post opening the session at $36.01, the shares hit an intraday low of $35.1801 and an intraday high of $36.05 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Jun 2, 2016, Kevin S. Wilson (CEO and President) sold 20,000 shares at $36.74 per share price. According to the SEC, on May 10, 2016, Sharon L. Riley (director) sold 5,000 shares at $36.87 per share price. On May 10, 2016, Michael J Mcginley (Presi, Biologic. & Pharm.) sold 5,998 shares at $36.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Heska Corporation develops manufactures markets sells and supports veterinary products. The Company is focused on the canine and feline companion animal health markets. The Company operates in two segments: Core Companion Animal Health and Other Vaccines Pharmaceuticals and Products. The Core Companion Animal Health segment (CCA) includes primarily for canine and feline use blood testing instruments and supplies digital imaging products software and services and single use products and services such as heartworm diagnostic tests heartworm preventive products allergy immunotherapy products and allergy testing. The Other Vaccines Pharmaceuticals and Products segment (OVP) includes private label vaccine and pharmaceutical production primarily for cattle but also for other animals including small mammals.